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Background: Steroid (glucocorticoid)-induced osteonecrosis of the femoral head (ONFH) in young adults
has been a challenging disorder due to frequent incidence of collapse of the femoral head and resulting
dysfunction of the hip joint and impairing quality of life. In Japan, the working group on ONFH in the
Speciﬁc Disease Investigation Committee under auspices of the Japanese Ministry of Health, Labor and
Welfare was founded in 1975, clinical and related basic research on ONFH have been continued for more
than 40 years.
Epidemiology and clinical course: A national epidemiologic survey in 2004 estimated that 2200 new
patients per year would be diagnosed with ONFH in Japan. ONFH was associated with steroid intake
(51%), heavy alcohol intake (31%), both (3%), and neither (15%). The male-to-female ratio was 5:4, and the
peak decades of age at deﬁnitive diagnosis were the 40s in male patients and the 30s in females. MRI
studies revealed that ONFH would have occurred in early phase after start of steroid administration and
no expansion of necrotic lesion within the femoral head in spite of continued steroid use. To standardize
ONFH diagnosis and treatment strategy, the Committee established validated diagnostic criteria, a
radiological staging system, and type categorization.
Treatment options: Most symptomatic patients with collapse of the femoral head require various surgical
procedures. Joint preserving surgery, such as transtrochanteric rotational osteotomy and curved varus
osteotomy, should be the treatment choice for young patients with healthy areas without severe collapse
of the femoral head.
Clinical and related basic research: Clinical and basic research has been performed to determine the
pathogenesis of steroid-induced ONFH. Low hepatic CYP3A activity has been reported to signiﬁcantly
contribute to the risk of steroid-induced ONFH. Several gene polymorphisms related to steroid meta-
bolism were shown to be associated with the occurrence of ONFH.
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Steroid (glucocorticoid)-induced osteonecrosis of the femoral
head (ONFH) in young adults has been a challenging disorder due to
frequent incidence of collapse of the femoral head and resulting
dysfunction of the hip joint and impairing quality of life. The causes
of ONFH have not been clariﬁed; however, studies have suggested
that this disease is associated with the administration of steroids in
patients with connective tissue diseases and organ transplant re-
cipients, as well as with heavy alcohol intake [1,2]. In particular,
steroid-induced ONFH, which may have iatrogenic aspects, occurs
frequently in adolescents and middle-aged patients. Therefore, it is
necessary to standardize diagnosis and treatment and to develop
highly reliable methods of prevention.
In 1975, the working group on ONFH in the Speciﬁc Disease
Investigation Committee (the Committee) was established under
the auspices of the Japanese Ministry of Health, Labor and Welfare
to conduct clinical and related basic research studies on ONFH.
Research has been ongoing for more than 40 years. The Committee
has continuously published the latest research results on aspects of
ONFH, including epidemiological surveys [2e4], diagnosis and
treatment [5,6], clinical [7e9] and basic research [10,11] and is
making a contribution on a global level.
This article discusses the epidemiology, pathology and treat-
ment of steroid-induced ONFH, based on the results of research
conducted by the Committee.2. Epidemiology
A national epidemiologic survey in 2004 estimated that
approximately 11,400 patients in Japan were treated for ONFHFig. 1. Age distribution (in years) of subjects at the time of diagnosis of ONFH. Analysis
was based on subjects of known age at the time of diagnosis.
Source: [3].annually, and that 2200 patients per year were newly diagnosed
with this disease. The male-to-female ratio was 5:4, and the peak
decades of age at deﬁnitive diagnosis were the 40s in male patients
and the 30s in females (Fig.1). ONFHwas estimated to be associated
with steroids in 51% of patients, with heavy alcohol intake in 31%,
with both in 3%, and with neither in 15%. ONFH was found to be
steroid-induced in 34% of male patients and in 76% of females. The
underlying diseases requiring steroid administration included
systemic lupus erythematosus (SLE) in 31.2%, nephritic syndrome in
6.3%, polymyositis/dermatomyositis in 4.9%, asthma in 4.5%,
thrombocytopenic purpura in 4.4%, and other connective tissue
diseases in the remainder [3]. A multi-institutional caseecontrol
study found that the risk of ONFH was 20-fold higher in patients
with than without a history of oral steroid administration [4].
Caseecontrol studies were performed in Japanese SLE patients
[12] and kidney transplant recipients [13] to determine the asso-
ciation between steroid dose and ONFH. These studies, which
assessed the association between occurrence of ONFH and accu-
mulated steroid dose in a year, maximum dose and average daily
dose, found that average daily steroid dose had the strongest effect
on occurrence of ONFH. SLE patients receiving more than 16.6 mg/
day prednisolone had a 3.4-fold higher risk of ONFH comparedwith
patients receiving less than 12.3 mg/day [12]. Similarly, kidney
transplant recipients receiving more than 20.40 mg/day predniso-
lone had a 5.0-fold higher risk of ONFH compared with patients
receiving less than 14.92 mg/day [13].
The multifocal osteonecrosis associated with steroid adminis-
tration may occur not only in femoral heads but in humeral heads,
knee joints and ankle joints. It was reported that 91% of patients
with multifocal osteonecrosis had a history of steroid administra-
tion [14]. An MRI screening study of 250 patients with steroid
induced ONFH found osteonecrosis in 50% of knees and 24% of
humeral heads [15].3. Clinical course of steroid-induced ONFH
In spite of many extensive studies of ONFH, it has been obscure
howONFH occur after start of steroid use. However, timing of ONFH
occurrence after start of steroid use was investigated by time
sequential MRI in a cohort of renal transplantation recipients with
postoperative steroid use for the purpose of immuno-suppression.
With the exception of cases who failed to be MR imaged until 12
month postoperatively, all ONFH lesions were ﬁrst detected on MRI
within 16 week after transplantation [7,16]. Thus, steroid-induced
ONFH would occur in early stage of steroid therapy. In consid-
ering other MRI study result in traumatic ONFH that advent of the
T1 weighted band image on MRI was noted 4 weeks after inter-
ruption of blood circulation by the fracture [17], the onset of ONFH
caused by ischemic attack in femoral head might assumed to occur
2e12 weeks after start of steroid use.
In those ONFH patients, symptom (hip pain), which would be
caused by collapse of the femoral head, started 6 months to 2 years
after renal transplantation and the start of steroid use (Fig. 2) [7].
Similar intervals from the start of steroid use to hip symptom (1e4
years) was reported by other authors in a SLE cohort [8].
For ONFH patients requiring continuation of steroid use for the
treatment of back ground diseases, there might be concerns for
Fig. 2. Progression of ONFH after renal transplantation. a. T1-weighted MRI of hip
joints 12 weeks after renal transplantation. T1 low-intensity band patterns were
observed in the bilateral femoral head. b. Plain radiograph of hip joints 12 weeks after
renal transplantation. No abnormal ﬁndings were observed in the femoral head. c.
Plain radiograph of hip joints one year after renal transplantation. Demarcation of
sclerosis and collapse were observed in the bilateral femoral head.
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necrosis in other sites. The studies to address this concern indicated
no expansion of the necrotic lesion with continuous use of steroid
[7]. And once the site and size of the necrotic lesion were ﬁxed,
additional bone necrosis lesions were extremely rare to appear
[18,19]. Sugano et al. reported that shift from unilateral ONFH cases
to bilateral cases is very rare (2%) [20].
These observations suggested that the prognosis of the affected
hip can be predicted based on the initial position and size of theTable 1
Diagnostic criteria for osteonecrosis.
Collapse of the femoral head without joint space narrowing or acetabular abnormality
Demarcating sclerosis in the femoral head without joint-space narrowing or acetabula
“Cold in hot” on bone scans
Low intensity band on MR T1-weighted images (band like pattern) within the femora
Trabecular and marrow necrosis on histology
Deﬁnite diagnosis requires any two positive criteria out of the ﬁve.
Bone tumors and dysplasias should be excluded.necrotic area. Moreover, as the rate of recurrence is low even if
steroids are continued, there is no need to reduce steroid dosage or
discontinue their administration after the occurrence of ONFH,
since steroids remain necessary to control the underlying disease.4. Diagnosis and treatment strategy for ONFH
The Committee devised a tool for diagnosis consisting of 5
characteristic features of typical ONFH on plain radiograph, bone
scintigram, MRI and bone biopsy ﬁndings (Table 1) [5]. Validity of
the diagnostic tool was examined in patients with hip disorders
with histology of excised whole femoral head as gold standard.
Sensitivity and speciﬁcity of the diagnostic tool were calculated to
be 91% and 99%, respectively [6].
In order to predict prognosis of ONFH in early stage, Four types
(A, B, C1 and C2) were classiﬁed based on size and location of
necrotic area on A/P X-ray and/or MRI mid-coronal image of the
femoral head, i.e. depending on location of subchondral necrotic
bone mass in relation to acetabular weight bearing surface line
(Fig. 3) [5]. Survivorship of the ONFH hips without femoral head
collapse in respective groups was already reported [21]. Poor
prognosis was consistently shown in type C (C1 and C2) group.
Identiﬁcation of stage of destructive changes in ONFH also would
be important step to ﬁnd optimal surgical option. And the Com-
mittee has presented a grading system (Table 2, Fig. 4), based on the
occurrence of the femoral head collapse and osteoarthritic changes
[5]. The Committee recommends deciding optimal surgical treat-
ment by considering type and stage of the ONFH as described
below.4.1. Conservative treatment
Natural courses of the early ONFH without collapse were
observed in time sequence without any treatment and presented
in several reports [21e23]. A systematic review found that types A,
B and C hip collapses occur in 9%, 19%, and 59% of ONFH patients,
respectively [21]. In addition, cessation of collapse and improve-
ment of symptoms without surgical intervention can occur in
patients with type A and B hips once the femoral head has
collapse [23,24]. Most of type A hips survived without collapse
and progressive symptoms. Therefore, type A and type B hips with
no or mild symptom would allow to be observed without treat-
ment. But poor prognosis was predominantly seen in type C group
hips. Type C hips and a part of type B hips frequently progress to
collapse and would be candidates for surgery despite use of
analgesics.
As collapse is the major cause of symptom, prevention of
collapse with drugs, if possible, might be a target of conservative
treatment. Administration of bisphosphonate was reported to
prevent collapse in early stage ONFH in small groups of patients
[24]. However, prolonged anti-collapse effect of bisphosphonates
was not elucidated yet. Further extensive studies with long-term
observation would be warranted.on X-rays (including crescent sign)
r abnormality on X-rays
l head
Fig. 3. 2001 revised classiﬁcation of osteonecrosis. The classiﬁcation scheme consists of four types (A, B, C1, and C2) and is based on the anteroposterior X-rays or mid-coronal
section of the femoral head on T1-weighted MR images. Type A lesions occupy the medial one third or less of the weight-bearing portion. Type B lesions occupy the medial two
thirds or less of the weight-bearing portion. Type C1 and type C2 lesions both occupy more than the medial two thirds or less of the weight-bearing portion; type C2 lesions extend
laterally to the acetabular edge type, whereas C1 lesions do not. The weight-bearing portion is deﬁned as the area lateral to the mid-vertical line of the line through the acetabular
edge and the teardrop bottom.
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Surgery is indicated in patients with symptoms that are ex-
pected to progress to collapse of the femoral head. Surgical
methods to treat ONFH would largely be classiﬁed to two cate-
gories, joint preserving surgeries and prosthetic replacement sur-
geries. The joint preserving surgical procedures would include core
decompression with or without bone grafting (non-vascularized or
vascularized), transtrochanteric osteotomy (transtrochanteric
anterior or posterior rotational osteotomy (TRO)) and curved varus
osteotomy (CVO). According to multicenter survey by the Com-
mittee in 2007, joint preserving surgeries were underwent in 1/4
cases and prosthesis replacing surgeries in 2/3 cases in Japan [25].
The joint preserving surgeries were ordinarily indicated for young
or middle-aged patients without collapse (stage 2) or with mild
collapse (stage 3A).
Before MRI became common, core decompression (core biopsy)
was the most reliable diagnostic modality for ONFH [26]. A recent
review article indicated that core decompression provides favor-
able outcomes only in patients with small necrotic lesions [27].
However, anti-collapse effect of the core decompression in early
stage of has been controversy. Since Sugano et al. reported little
anti-collapse effect of the core decompression in high collapse risk
type C [28], this surgery without bone grafting would rarely be
indicated in Japan.
Non-vascularized bone grafting for early-stage ONFH has been
reported [29], but this procedure has not been widely adopted.
Previously, vascularized bone grafting from iliac crest or ﬁbula after
curettage of necrotic bone mass was attempted but clinical results
were not always successful due to post-operative progression of
collapse, in despite of bone defects at graft harvesting sites and
demanding skills of micro-surgery [30,31].
The principle goals of osteotomy for ONFH are to avoid load
stimulation on necrotic parts, and to achieve joint congruity by
returning the femoral head from the subluxation to the concentricTable 2
Staging system for ONFH.
Stage 1. There are no speciﬁc ﬁndings of osteonecrosis on X-ray images. However, spe
Stage 2. Demarcating sclerosis in seen without collapse of the femoral head.
Stage 3. Collapse of the femoral head, including crescent sign, is seenwithout joint-spac
seen.
Stage 3A. Collapse of the femoral head is less than 3 mm
Stage 3B. Collapse of the femoral head is 3 mm or grater
Stage 4. Osteoarthritic changes are seen
Staging should be based on both anteroposterior and lateral X-ray views of the femoral
direction while the patient is positioned supine with the hip in 90 of ﬂexion, 45 oposition. Currently, good clinical results have been reported in cases
of TRO and CVO in early stages (stage 2 or 3) [32e34]. TRO is aimed
at shift of the necrotic bonemass fromweight-bearing sub-chondral
part and to be replaced with healthy bone with smooth cartilage
surface through anterior or posterior rotation of the femoral head
and neck around femoral neck axis after inter-trochanteric osteot-
omy (Fig. 5). TRO ismainly indicated in patients with type C-1 and C-
2 hips, in which healthy areas remain in the anterior or posterior
part of the weight-bearing area. Decision of anterior or posterior
rotation was ordinarily made depending on location of the necrotic
bone mass on lateral radiograph. Anterior rotational osteotomy
would be recommended when the necrotic bone mass in the
femoral head located anterior part under weight-bearing surface to
the femoral head. Since the necrotic bone mass shift outside of the
weight-bearing surface and healthy mass locating posterior part of
the head shift to weight-bearing surface, resulting higher rate of
coverage of the femoral weight-bearing surface with healthy bone
and cartilage. When the subchondral necrotic mass locates more
cranial or posterior part of the femoral head, posterior rotational
osteotomy would be recommended due to the concept described
above. Success rates in previous reports of TRO were around 80%
[32,33]. Preservation of vasculature to the femoral head was re-
ported to essential to obtain good clinical results and great care
should be taken intra-operatively to avoid damage to vasculature to
femoral head. Based on recent follow-up studies of the post-
operative patients of TRO, the ratio of shifted healthy joint surface
to acetabular weight-bearing on A/P radiograph appeared to be a
critical factor for long term hip function, and the ratiomore than 34%
would be necessary to keep good hip function [35].
The aim of CVO was similar to the rotational osteotomies. By
CVO, healthy bone and cartilage in lateral part of the head was
shifted to weight-bearing part of the head (Fig. 6). But the shift
distance of the healthy bone mass was limited compared with TRO.
And this osteotomy would be indicated to symptomatic type B and/
or type C-1. In comparison with TRO, advantages of this osteotomyciﬁc ﬁndings are observed on MRI, bone scintigram, or histology.
e narrowing. Mild osteophyte formation of the femoral head or acetabulummay be
head. The lateral view of the femoral head should be taken in the anteroposterior
f abduction, and neutral rotation, according to the Sugioka method.
Fig. 4. Radiographic ﬁndings of the staging system for ONFH. a. Stage 1. No speciﬁc ﬁndings on plain radiographs, but a low-intensity band pattern was observed on T1-weighted
MRI. b. Stage 2. Demarcation of sclerosis observed in the femoral head (arrows). c. Stage 3A. d. Stage 3B. e. Stage 4.
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and not requiring highly demanding surgical skill [34].
Regarding prosthetic replacement surgery, bipolar hip arthro-
plasty (BHA) had been one of routine options for ONFH patient until
recent years due to simple surgical procedures and preserved
acetabular bony structure. But later follow-up studies of those pa-
tients indicated high rate of progressive central migration of
prosthesis, stem loosening and revision surgery [36,37]. Previously,
clinical outcome of total hip arthroplasty (THA) in ONFH had been
deﬁnitely inferior to that of osteoarthritis (OA) due to high rate ofFig. 5. Transtrochanteric anterior rotational osteotomy of the femoral head. a. Plain radiograp
The necrotic area was shifted medially.loosening, dislocation and subsequent limited survivorship due to
high demands to physical activity [38]. But modern THA is accepted
for major treatment of choice for ONFH patients despite of younger
mean age of those patients compared with that of OA patients. This
might resulted from signiﬁcant improvement of prosthesis (bio-
materials, design, and porous surface) and modern surgical tech-
nique. And survivorship of the THA in ONFH patients was signiﬁ-
cantly improved and equivalent to that in OA patients [39]. One of
the remaining concerns for THA in ONFH patients is high rate of
post-operative dislocation compared with that in OA patients [40].h of hip joint before surgery, showing Type C-2 ONFH. b. Plain radiograph after surgery.
Fig. 6. Curved intertrochanteric varus osteotomy. a. Plain radiograph of hip joint before surgery, showing Type C-1 ONFH. b. Plain radiograph after surgery. The necrotic area was
shifted medially.
T. Kubo et al. / Journal of Orthopaedic Science 21 (2016) 407e413412Use of large ball, double bearing prosthesis and/or anterior
approach would be recommended to avoid the dislocation.
5. Clinical and related basic research on ONFH
In order to elucidate patho-mechanism of steroid-induced
ONFH, lots of experimental projects were designed and per-
formed by the Committee members. The pathogenesis of steroid-
induced ONFH has been reported to involve oxidative stress [41],
disorders of the vascular endothelium [42], blood coagulation
disorders, abnormal lipid metabolism [43], fat embolism [44] and
apoptosis [45]. Recent topic on mechanism of steroid was
oxidative stress, which might damage vascular endothelial
cells of arteries or arterioles to incite ischemic attack within
femoral head. Thus excessive oxidative stress potentially causes
ischemic bone necrosis [11,41]. Therefore, amelioration of the
oxidative stress with anti-oxidative drugs, like vitamin E, might
be effective to prevent bone necrosis by concomitant adminis-
tration with steroid. Administration of vitamin E has been
found to prevent steroid-induced osteonecrosis in animal models
[46]. This hypothesis should be substantiated in following
studies.
Regarding individual difference in susceptibility to steroid
induced ONFH, Kaneshiro et al. evaluated steroid metabolizing
enzyme hepatic cytochrome P450 (CYP) 3A enzyme activity by
measuring midazoram clearance and concluded that CYP3A ac-
tivity in steroid-induced ONFH patient was consistently lower
than standard level of normal population [9]. And he speculated
that patients with low steroid metabolizing capacity would be
exposed to higher level of steroid for prolonged period time, and
resulting toxic effects, e.g., high level of oxidative stress. By
regulating CYP3A capacity with agents inducing or suppressing
the CYP3A enzymatic activity, association of CYP3A activity with
vulnerability to steroid induced bone necrosis was shown in a
rabbit model [10].
Some renal transplant recipients develop steroid-induced
ONFH, while others receiving the same steroid administration
protocol do not [47]. These inter-individual differences may be
associated with genetic polymorphisms. Single nucleotide poly-
morphisms (SNPs) of P-glycoprotein (P-gp), a transport protein thatexports drugs such as steroids from inside to outside the cell [48],
and of glucocorticoid receptors [49] have been found to affect the
occurrence of ONFH.6. Summary
This report provided an overview of the clinical and related
basic research on ONFH conducted by the Committee. The number
of ONFH patients and the risks of steroid administration were
demonstrated by the national epidemiologic survey. MRI showed
that early stage, asymptomatic ONFH occurred soon after starting
steroid administration, with no expansion of necrotic lesions
within the femoral head despite continued steroid use. To stan-
dardize ONFH diagnosis and treatment, the Committee established
diagnostic criteria, a radiological staging system, and type catego-
rization. Categorizing disease stage and type following a diagnosis
of ONFH enables selection of the appropriate treatment. Clinical
studies showed that low hepatic CYP3A activity and several gene
polymorphisms were signiﬁcantly associated with the risk of
steroid-induced ONFH. Intensive basic research has been per-
formed to clarify the pathogenesis of ONFH.Conﬂict of interest
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